- ZS Pharma (ZSPH) is a late-stage biotech developing a treatment for excess potassium (hyperkalemia)
- Offered 5.0 million shares
- ZS Pharma was founded in 2008, booked $0 million in sales over the last 12 months.
- Coppell, TX-based company
- J.P. Morgan and Credit Suisse are the joint bookrunners on the deal.
Description
ZS Pharma, Inc is a biopharmaceutical company focused on the development and commercialization of selective, non-absorbed drugs to treat renal, cardiovascular, liver and metabolic diseases. The Company’s zirconium silicate technology allows it to create selective ion traps that can reduce toxic levels of specific electrolytes without disturbing the balance of other electrolytes. Its initial focus is on the development of ZS-9, its product candidate in Phase III development for the treatment of hyperkalemia, a life-threatening condition in which elevated levels of potassium in the blood increase the risk of muscle dysfunction, including cardiac arrhythmias and sudden cardiac death. The Company has completed two clinical studies with ZS-9 that together enrolled 843 patients with hyperkalemia, including patients with chronic kidney disease, (CKD), heart failure (HF), diabetes and those on renin-angiotensin aldosterone system (RAAS), inhibitor therapy.
Key stats and ratios
| Q1 (Mar '14) | 2013 | |
| Net profit margin | - | - |
| Operating margin | - | - |
| EBITD margin | - | - |
| Return on average assets | -189.69% | -169.42% |
No comments:
Post a Comment